These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20102992)

  • 1. The dynamics of chronic gout treatment: medication gaps and return to therapy.
    Harrold LR; Andrade SE; Briesacher B; Raebel MA; Fouayzi H; Yood RA; Ockene IS
    Am J Med; 2010 Jan; 123(1):54-9. PubMed ID: 20102992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping progression to tophaceous gout. When and how to use urate-lowering therapy.
    McDonald E; Marino C
    Postgrad Med; 1998 Dec; 104(6):117-20, 123-4, 127. PubMed ID: 9861261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better outcomes for patients with gout.
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S
    Inflammopharmacology; 2020 Oct; 28(5):1395-1400. PubMed ID: 32095979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
    Kolyvanos Naumann U; Suter PM; Käser L; Vetter W
    Praxis (Bern 1994); 2005 Apr; 94(14):543-8; quiz 549. PubMed ID: 15849976
    [No Abstract]   [Full Text] [Related]  

  • 10. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
    Perez-Ruiz F; Calabozo M; Herrero-Beites AM; García-Erauskin G; Pijoan JI
    Nephron; 2000 Nov; 86(3):287-91. PubMed ID: 11096285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
    Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
    Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gout: an update.
    Eggebeen AT
    Am Fam Physician; 2007 Sep; 76(6):801-8. PubMed ID: 17910294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence with urate-lowering therapies for the treatment of gout.
    Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
    Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
    Dalbeth N; Billington K; Doyle A; Frampton C; Tan P; Aati O; Allan J; Drake J; Horne A; Stamp LK
    Arthritis Rheumatol; 2019 Oct; 71(10):1739-1746. PubMed ID: 31081595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
    Perez-Ruiz F; Herrero-Beites AM; Carmona L
    Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.